menu

Loading...

APUS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.375

Open

1.320

VWAP

1.32

Vol

20.50K

Mkt Cap

16.98M

Low

1.290

Amount

27.09K

EV/EBITDA(TTM)

--

Total Shares

12.58M

EV

--

EV/OCF(TTM)

--

P/S(TTM)

--

Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Show More

Events Timeline

(ET)

2026-02-11

17:00:00

Apimeds and Lundefinedkahi Confirm FDA Meeting to Discuss LT-100

2025-12-01 (ET)

2025-12-01

10:00:00

Apimeds Pharmaceuticals US Inc Trading Resumes

2025-12-01

09:40:00

Apimeds Merges with MindWave Innovations to Create Dual-Growth Enterprise

2025-12-01

09:10:00

Apimeds Pharmaceuticals US Inc Trading Halted, News Pending

2025-10-14 (ET)

2025-10-14

05:28:37

Apimeds Pharmaceuticals broadens its AI Futures Lab initiative

2025-09-12 (ET)

2025-09-12

05:17:59

Apimeds Pharmaceuticals Releases Statement Regarding FDA's Draft Guidance on Pain Management Program

News

Newsfilter

02-11Newsfilter

Apimeds and Lōkahi Secure FDA Meeting Confirmation for LT-100

renaissancecapital

2025-12-23renaissancecapital

Three Small IPOs Set to Raise $46 Million Next Week

Globenewswire

2025-12-17Globenewswire

E.F. Hutton Facilitates APUS and Mindwave Merger with $100 Million PIPE Financing

Newsfilter

2025-12-17Newsfilter

E.F. Hutton Facilitates $100M Merger Between Apimeds and Mindwave Innovations

Newsfilter

2025-12-10Newsfilter

Apimeds Closes $100 Million PIPE Financing to Advance Non-Opioid Therapies

Newsfilter

2025-12-01Newsfilter

Apimeds Merges with MindWave, Secures Up to $100 Million Financing

Valuation Metrics

The current forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Apimeds Pharmaceuticals US Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding APUS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Apimeds Pharmaceuticals US Inc (APUS) stock price today?

The current price of APUS is 1.3 USD — it has decreased -3.7

What is Apimeds Pharmaceuticals US Inc (APUS)'s business?

Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

What is the price predicton of APUS Stock?

Wall Street analysts forecast APUS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APUS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Apimeds Pharmaceuticals US Inc (APUS)'s revenue for the last quarter?

Apimeds Pharmaceuticals US Inc revenue for the last quarter amounts to -1.84M USD, increased 514.75

What is Apimeds Pharmaceuticals US Inc (APUS)'s earnings per share (EPS) for the last quarter?

Apimeds Pharmaceuticals US Inc. EPS for the last quarter amounts to -1748706.00 USD, decreased

How many employees does Apimeds Pharmaceuticals US Inc (APUS). have?

Apimeds Pharmaceuticals US Inc (APUS) has 2 emplpoyees as of March 03 2026.

What is Apimeds Pharmaceuticals US Inc (APUS) market cap?

Today APUS has the market capitalization of 16.98M USD.